We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+39.2%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.59B
AUM Growth
+$505M
Cap. Flow
+$206M
Cap. Flow %
12.97%
Top 10 Hldgs %
57.57%
Holding
93
New
29
Increased
21
Reduced
9
Closed
17

Top Buys

Rank Stock Value
1
AKUS
Akouos Inc
AKUS
+$33.8M
2
GILD icon
Gilead Sciences
GILD
+$30.9M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$26.9M
4
LLY icon
Eli Lilly
LLY
+$22.9M
5
ABBV icon
AbbVie
ABBV
+$17.8M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$27.6M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$20.4M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.6M
4
BIIB icon
Biogen
BIIB
+$16.6M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.94M

Sector Composition

Rank Sector Weight
1 Healthcare 90.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$210M 13.25%
1,885,602
– –
ASND icon
2
Ascendis Pharma A/S
ASND
$16.7B
$164M 10.35%
1,109,874
– –
NTRA icon
3
Natera
NTRA
$37.5B
$155M 9.75%
3,100,560
– –
YMAB
4
DELISTED
Y-mAbs Therapeutics
YMAB
$94.8M 5.98%
2,194,278
– –
PRNB
5
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$84.7M 5.34%
1,417,258
– –
NXTC icon
6
NextCure
NXTC
$17.3M
$57.3M 3.61%
222,655
– –
AMGN icon
7
PUT
Amgen
AMGN
$203B
$39.7M 2.51%
+168,500
New +$38.4M
UTHR icon
8
United Therapeutics
UTHR
$26.3B
$36.9M 2.32%
304,562
+71,003
+30% +$7.99M
AMRN
9
Amarin Corp
AMRN
$284M
$36M 2.27%
260,415
– –
MRK icon
10
Merck
MRK
$324B
$34.9M 2.2%
472,835
-13,222
-3% -$995K
CHRS icon
11
Coherus Oncology
CHRS
$217M
$34.5M 2.18%
1,933,221
– –
AKUS
12
DELISTED
Akouos Inc
AKUS
$34.1M 2.15%
+1,515,073
New +$33.8M
GILD icon
13
Gilead Sciences
GILD
$161B
$31M 1.96%
+403,494
New +$30.9M
OBSV
14
DELISTED
ObsEva SA Ordinary Shares
OBSV
$28M 1.76%
4,749,623
– –
JAZZ icon
15
Jazz Pharmaceuticals
JAZZ
$15.9B
$26.9M 1.69%
+243,353
New +$26.9M
ABBV icon
16
AbbVie
ABBV
$458B
$24.7M 1.56%
251,959
+201,959
+404% +$17.8M
LLY icon
17
Eli Lilly
LLY
$1.07T
$24.4M 1.54%
+148,900
New +$22.9M
PTCT icon
18
PTC Therapeutics
PTCT
$6.37B
$22.2M 1.4%
438,270
+146,053
+50% +$7.18M
ALNY icon
19
CALL
Alnylam Pharmaceuticals
ALNY
$36.3B
$22.2M 1.4%
150,000
+122,900
+454% +$16.6M
GRTX
20
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$22M 1.39%
3,083,712
– –
MRUS
21
DELISTED
Merus
MRUS
$21.1M 1.33%
1,311,039
-650,000
-33% -$9.4M
XLRN
22
DELISTED
Acceleron Pharma
XLRN
$20.7M 1.31%
217,390
+52,230
+32% +$5.03M
KNSA icon
23
Kiniksa Pharmaceuticals
KNSA
$4.83B
$20.6M 1.3%
809,803
-112,897
-12% -$2.36M
XNTK icon
24
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.06B
$16.8M 1.06%
+150,000
New +$13.2M
XLV icon
25
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$42.1B
$15M 0.95%
+150,000
New +$14.8M
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2020 Portfolio in Review

As of Q2 2020, Sofinnova Investments held 93 positions worth $1.59B, up 47% from $1.08B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Sofinnova Investments deployed $206M of net new capital in Q2 2020, opening 29 new positions and adding to 21 existing holdings. Its largest new stake was Akouos Inc: 1,515,073 shares worth $34.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 96% a quarter earlier.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $17.6M trimmed.

  • Sofinnova Investments's largest Q2 2020 buy was Akouos Inc: 1,515,073 shares worth $34.1M.
  • Sofinnova Investments added most to AbbVie in Q2 2020, an estimated $17.8M increase.
  • Sofinnova Investments's biggest Q2 2020 reduction was BioMarin Pharmaceuticals, cutting an estimated $17.6M.
  • Sofinnova Investments fully exited Alexion Pharmaceuticals in Q2 2020, selling an estimated $27.6M.
  • Sofinnova Investments's ten largest holdings make up 58% of its $1.59B portfolio in Q2 2020.
  • Sofinnova Investments opened 29 new positions and closed 17 in Q2 2020.
  • Sofinnova Investments's portfolio value rose 47% quarter-over-quarter to $1.59B.

Based on Sofinnova Investments's 13F filing for Q2 2020, filed 13 Aug 2020.